Skip to main content
Erschienen in: Clinical & Experimental Metastasis 1/2015

01.01.2015 | Research Paper

Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma

verfasst von: Sabrina Daniela da Silva, Grégoire B. Morand, Faisal A. Alobaid, Michael P. Hier, Alex M. Mlynarek, Moulay A. Alaoui-Jamali, Luiz Paulo Kowalski

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Multiple primary tumors can occur in up to 35 % of the patients with head and neck cancer, however its clinicopathological features remain controversial. Deregulation of epithelial-mesenchymal transition (EMT) signaling has been associated with aggressive malignancies and tumor progression to metastasis in several cancer types. This study is the first to explore EMT process in multiple primary oral squamous cell carcinomas (OSCC). Immunohistochemical analysis of E-cadherin, catenin (α, β, and γ), APC, collagen IV, Ki-67, cyclin D1, and CD44 were performed in a tissue microarray containing multiple representative areas from 102 OSCC patients followed-up by at least 10 years. Results were analysed in relation to clinicopathological characteristics and survival rates in patients presenting multiple primary tumors versus patients without second primary tumors or metastatic disease. Significant association was observed among multiple OSCCs and protein expression of E-cadherin (P = 0.002), β-catenin (P = 0.047), APC (P = 0.017), and cyclin D1 (P = 0.001) as well as between lymph nodes metastasis and Ki-67 staining (P = 0.021). OSCCs presenting vascular embolization were associated with negative β-catenin membrane expression (P = 0.050). There was a significantly lower survival probability for patients with multiple OSCC (log-rank test, P < 0.0001), for tumors showing negative protein expression for E-cadherin (log-rank test, P = 0.003) and β-catenin (log-rank test, P = 0.031). Stratified multivariate survival analysis revealed a prognostic interdependence of E-cadherin and β-catenin co-downexpression in predicting the worst overall survival (log-rank test, P = 0.007). EMT markers have a predicted value for invasiveness related to multiple primary tumors in OSCC and co-downregulation of E-cadherin and β-catenin has a significant prognostic impact in these cases.
Literatur
1.
Zurück zum Zitat Billroth T (1882) Die Allgemeine Chirurgische Pathologie und Therapie In 51 Vorlesungen: Ein Handbuch für Studierende und Aerzte. R Riemer, Berlin 980 Billroth T (1882) Die Allgemeine Chirurgische Pathologie und Therapie In 51 Vorlesungen: Ein Handbuch für Studierende und Aerzte. R Riemer, Berlin 980
2.
Zurück zum Zitat Gan SJ et al (2013) Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer 119(14):2593–2601PubMedCentralPubMedCrossRef Gan SJ et al (2013) Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer 119(14):2593–2601PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Bold B et al (2008) Usefulness of PET/CT for detecting a second primary cancer after treatment for squamous cell carcinoma of the head and neck. Clin Nucl Med 33(12):831–833PubMedCrossRef Bold B et al (2008) Usefulness of PET/CT for detecting a second primary cancer after treatment for squamous cell carcinoma of the head and neck. Clin Nucl Med 33(12):831–833PubMedCrossRef
4.
Zurück zum Zitat van Oijen MG et al (2000) The origins of multiple squamous cell carcinomas in the aerodigestive tract. Cancer 88(4):884–893PubMedCrossRef van Oijen MG et al (2000) The origins of multiple squamous cell carcinomas in the aerodigestive tract. Cancer 88(4):884–893PubMedCrossRef
5.
Zurück zum Zitat Stokkel MP et al (1999) 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 86(11):2370–2377PubMedCrossRef Stokkel MP et al (1999) 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 86(11):2370–2377PubMedCrossRef
6.
Zurück zum Zitat McGarry GW et al (1992) Multiple primary malignant tumours in patients with head and neck cancer: the implications for follow-up. Clin Otolaryngol Allied Sci 17(6):558–562PubMedCrossRef McGarry GW et al (1992) Multiple primary malignant tumours in patients with head and neck cancer: the implications for follow-up. Clin Otolaryngol Allied Sci 17(6):558–562PubMedCrossRef
7.
Zurück zum Zitat Liao LJ et al (2013) The impact of second primary malignancies on head and neck cancer survivors: a nationwide cohort study. PLoS One 8(4):e62116PubMedCentralPubMedCrossRef Liao LJ et al (2013) The impact of second primary malignancies on head and neck cancer survivors: a nationwide cohort study. PLoS One 8(4):e62116PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968PubMedCrossRef Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968PubMedCrossRef
9.
10.
Zurück zum Zitat Califano J et al (2000) Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 6(2):347–352PubMed Califano J et al (2000) Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 6(2):347–352PubMed
11.
Zurück zum Zitat Califano J et al (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56(11):2488–2492PubMed Califano J et al (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56(11):2488–2492PubMed
12.
Zurück zum Zitat Braakhuis BJ et al (2002) Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24(2):198–206PubMedCrossRef Braakhuis BJ et al (2002) Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24(2):198–206PubMedCrossRef
13.
14.
Zurück zum Zitat Bedi GC et al (1996) Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 56(11):2484–2487PubMed Bedi GC et al (1996) Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 56(11):2484–2487PubMed
15.
Zurück zum Zitat Koukourakis MI et al (2012) Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer 106(5):846–853PubMedCentralPubMedCrossRef Koukourakis MI et al (2012) Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer 106(5):846–853PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Yang CC et al (2013) Membrane type 1 matrix metalloproteinase induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. BMC Cancer 13:171PubMedCentralPubMedCrossRef Yang CC et al (2013) Membrane type 1 matrix metalloproteinase induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. BMC Cancer 13:171PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat La Fleur L, Johansson AC, Roberg K (2012) A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One 7(9):e44071PubMedCentralPubMedCrossRef La Fleur L, Johansson AC, Roberg K (2012) A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS One 7(9):e44071PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Biddle A, Mackenzie IC (2012) Cancer stem cells and EMT in carcinoma. Cancer metastasis rev 31(1–2):285–293CrossRef Biddle A, Mackenzie IC (2012) Cancer stem cells and EMT in carcinoma. Cancer metastasis rev 31(1–2):285–293CrossRef
19.
Zurück zum Zitat Chen C et al (2013) Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Lett 338(1):47–56PubMedCrossRef Chen C et al (2013) Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Lett 338(1):47–56PubMedCrossRef
20.
Zurück zum Zitat Berx G et al (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24(8):587–597PubMedCrossRef Berx G et al (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis 24(8):587–597PubMedCrossRef
21.
22.
Zurück zum Zitat Edme N et al (2002) Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J Cell Sci 115(12):2591–2601PubMed Edme N et al (2002) Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J Cell Sci 115(12):2591–2601PubMed
23.
Zurück zum Zitat Lo Muzio L (2001) A possible role for the WNT-1 pathway in oral carcinogenesis. Crit Rev Oral Biol Med 12(2):152–165PubMedCrossRef Lo Muzio L (2001) A possible role for the WNT-1 pathway in oral carcinogenesis. Crit Rev Oral Biol Med 12(2):152–165PubMedCrossRef
24.
Zurück zum Zitat Boyer B, Valles AM, Edme N (2000) Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60(8):1091–1099PubMedCrossRef Boyer B, Valles AM, Edme N (2000) Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 60(8):1091–1099PubMedCrossRef
25.
Zurück zum Zitat O’Sullivan B, Shah J (2003) New TNM staging criteria for head and neck tumors. Semin Surg Oncol 21(1):30–42PubMedCrossRef O’Sullivan B, Shah J (2003) New TNM staging criteria for head and neck tumors. Semin Surg Oncol 21(1):30–42PubMedCrossRef
26.
Zurück zum Zitat Wahi PN et al (1971) Histological typing of oral and oropharyngeal tumours. World Health Organization, Geneva, pp 17–18 Wahi PN et al (1971) Histological typing of oral and oropharyngeal tumours. World Health Organization, Geneva, pp 17–18
27.
Zurück zum Zitat da Silva SD et al (2014) TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. Cancer 120(3):352–362PubMedCrossRef da Silva SD et al (2014) TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. Cancer 120(3):352–362PubMedCrossRef
28.
Zurück zum Zitat Kononen J et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847PubMedCrossRef Kononen J et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847PubMedCrossRef
29.
Zurück zum Zitat Kokko LL et al (2011) Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 47(6):510–516PubMedCrossRef Kokko LL et al (2011) Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 47(6):510–516PubMedCrossRef
31.
Zurück zum Zitat Hafner C et al (2002) Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 101(1):1–6PubMedCrossRef Hafner C et al (2002) Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 101(1):1–6PubMedCrossRef
33.
Zurück zum Zitat Liu LK et al (2010) Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod pathol 23(2):213–224PubMedCrossRef Liu LK et al (2010) Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod pathol 23(2):213–224PubMedCrossRef
34.
Zurück zum Zitat Tanaka N et al (2003) Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer 89(3):557–563PubMedCentralPubMedCrossRef Tanaka N et al (2003) Expression of E-cadherin, alpha-catenin, and beta-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer 89(3):557–563PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Tanaka F et al (2013) Snail promotes Cyr61 secretion to prime collective cell migration and form invasive tumor nests in squamous cell carcinoma. Cancer Lett 329(2):243–252PubMedCrossRef Tanaka F et al (2013) Snail promotes Cyr61 secretion to prime collective cell migration and form invasive tumor nests in squamous cell carcinoma. Cancer Lett 329(2):243–252PubMedCrossRef
36.
Zurück zum Zitat Huber GF et al (2011) Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer 11(217):1–8PubMed Huber GF et al (2011) Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. BMC Cancer 11(217):1–8PubMed
37.
39.
Zurück zum Zitat Alami J, Williams BR, Yeger H (2003) Differential expression of E-cadherin and beta catenin in primary and metastatic Wilms’s tumours. Mol Pathol 56(4):218–225PubMedCentralPubMedCrossRef Alami J, Williams BR, Yeger H (2003) Differential expression of E-cadherin and beta catenin in primary and metastatic Wilms’s tumours. Mol Pathol 56(4):218–225PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Etienne-Manneville S (2008) Polarity proteins in migration and invasion. Oncogene 27(55):6970–6980PubMedCrossRef Etienne-Manneville S (2008) Polarity proteins in migration and invasion. Oncogene 27(55):6970–6980PubMedCrossRef
41.
Zurück zum Zitat Hanken H et al (2014) CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin Oral Invest 18(1):269–276CrossRef Hanken H et al (2014) CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clin Oral Invest 18(1):269–276CrossRef
42.
Zurück zum Zitat Klimowicz AC et al (2013) The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. Br J Cancer 109(7):1859–1866PubMedCentralPubMedCrossRef Klimowicz AC et al (2013) The prognostic impact of a combined carbonic anhydrase IX and Ki67 signature in oral squamous cell carcinoma. Br J Cancer 109(7):1859–1866PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Gonzalez-Moles MA et al (2010) Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. Oral Oncol 46(7):525–530PubMedCrossRef Gonzalez-Moles MA et al (2010) Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. Oral Oncol 46(7):525–530PubMedCrossRef
44.
Zurück zum Zitat Perisanidis C et al (2012) Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 41(1):40–46PubMedCrossRef Perisanidis C et al (2012) Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 41(1):40–46PubMedCrossRef
45.
Zurück zum Zitat Pich A, Chiusa L, Navone R (2004) Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 15(9):1319–1329PubMedCrossRef Pich A, Chiusa L, Navone R (2004) Prognostic relevance of cell proliferation in head and neck tumors. Ann Oncol 15(9):1319–1329PubMedCrossRef
47.
Zurück zum Zitat Hildebrand LC et al (2014) Spatial distribution of cancer stem cells in head and neck squamous cell carcinomas. J Oral Pathol Med 34(1):11–18 Hildebrand LC et al (2014) Spatial distribution of cancer stem cells in head and neck squamous cell carcinomas. J Oral Pathol Med 34(1):11–18
49.
Zurück zum Zitat Georgolios A et al (2006) The role of CD44 adhesion molecule in oral cavity cancer. Exp Oncol 28(2):94–98PubMed Georgolios A et al (2006) The role of CD44 adhesion molecule in oral cavity cancer. Exp Oncol 28(2):94–98PubMed
Metadaten
Titel
Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma
verfasst von
Sabrina Daniela da Silva
Grégoire B. Morand
Faisal A. Alobaid
Michael P. Hier
Alex M. Mlynarek
Moulay A. Alaoui-Jamali
Luiz Paulo Kowalski
Publikationsdatum
01.01.2015
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 1/2015
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9690-1

Weitere Artikel der Ausgabe 1/2015

Clinical & Experimental Metastasis 1/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.